News headlines about Endologix (NASDAQ:ELGX) have trended somewhat positive on Thursday, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Endologix earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned press coverage about the medical instruments supplier an impact score of 47.1988281459119 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have impacted Accern’s scoring:
- Endologix, Inc. (ELGX) stock price moves 0.22% up to an average price of last 20 days (thestocksnews.com)
- In-Depth Research: Abdominal Aortic Aneurysm (AAA) Repair Devices Market by Leading key players | Cook Medical … (journalhealthcare.com)
- Global Vascular Stents Market | 2018 Key Vendors: Medtronic, Abbott Laboratories, Endologix, MicroPort Scientific … (factsweek.com)
- Global Vascular Stents Market | 2018 Key Vendors: Medtronic, Abbott Laboratories, Endologix, plc, MicroPort Scientific … (factsweek.com)
- Global Stent Grafts Market 2018 – Cook Medical, Gore, Endologix, Bard, Terumo (healthcaretrends24.com)
Several research firms have recently issued reports on ELGX. Zacks Investment Research upgraded shares of Endologix from a “sell” rating to a “hold” rating in a report on Monday, March 19th. ValuEngine lowered shares of Endologix from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Oppenheimer set a $5.00 price objective on shares of Endologix and gave the stock a “hold” rating in a report on Thursday, February 22nd. BidaskClub upgraded shares of Endologix from a “sell” rating to a “hold” rating in a report on Saturday, February 10th. Finally, JPMorgan Chase lowered shares of Endologix from a “neutral” rating to an “underweight” rating in a report on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $5.41.
Endologix (NASDAQ:ELGX) last posted its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.13. Endologix had a negative net margin of 36.65% and a negative return on equity of 44.91%. The business had revenue of $44.00 million during the quarter, compared to the consensus estimate of $44.91 million. During the same quarter in the previous year, the firm posted ($0.30) EPS. The firm’s revenue was down 7.3% on a year-over-year basis. equities analysts expect that Endologix will post -0.73 earnings per share for the current fiscal year.
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.